Karin Rosén moves on from GSK, now playing dual roles at Horizon; Gilead looks to Jared Baeten to take command of HIV strategy
→ GSK and Genentech alum Karin Rosén is expanding her horizons, so to speak, taking on the roles of CSO and EVP, R&D at Horizon Therapeutics. Rosén departs for Horizon from her gig at GSK as SVP of US medical affairs, and she was a medical affairs exec at Aimmune before then for a short time. At Genentech, where she spent 10 years, she was promoted to therapeutic area head, immunology and worked on several Phase II/III programs in immunology, respiratory, allergy and dermatology.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.